Data Presented From Phase 2 Study of Enzalutamide in Advanced Androgen-Receptor Positive, Triple-Negative Breast Cancer

Information Presented From Stage 2 Study of Enzalutamide in Advanced Androgen-Receptor Good, Triple-Negative Breast Cancer Dec 12, 2014 – 23:07 GMT SAN FRANCISCO, CA and also TOKYO, JAPAN–(Marketwired – Dec 12, 2014) – Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (Tokyo: 4503), revealed today the presentation of Phase 1 [...] Read More